Brief: Inhibikase Therapeutics Announces FDA Has Lifted The Full Clinical Hold On Ikt-148009 In Parkinson's Disease
25/01/2023 13:12
Jan 25 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FDA HAS LIFTED THE FULL
CLINICAL HOLD ON IKT-148009 IN PARKINSON'S DISEASE
* INHIBIKASE THERAPEUTICS INC - PHASE 2A '201' CLINICAL
TRIAL WILL
RESUME IMMEDIATELY AT 50 AND 100 MG DOSES
Source text for Eikon: ID:nPnlBqpja
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share